Evidence map›Paper›PMID 42643345›Full record

ArticleFrontiers in pharmacology2026

Potential of isoquinoline-alkaloid-rich

Monika Dzięgielewska, Sylwia Zielińska, Taimoor Khan, Muhammad Suahib Qudus, Bartłomiej Dudek, Malwina Brożyna, Weronika Kozłowska, Adam Matkowski, Marzenna Bartoszewicz, Yanfang Sun and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Monika DzięgielewskaDziegielewska Eye Institute, Warsaw, Poland.
Sylwia ZielińskaDivision of Pharmaceutical Biotechnology, Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Wrocław, Poland.
Taimoor KhanCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Muhammad Suahib QudusCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Bartłomiej Dudek"P.U.M.A." Platform for Unique Model Application, Department of Translative Technologies, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.
Malwina Brożyna"P.U.M.A." Platform for Unique Model Application, Department of Translative Technologies, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.
Weronika KozłowskaDivision of Pharmaceutical Biotechnology, Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Wrocław, Poland.
Adam MatkowskiDivision of Pharmaceutical Biology and Botany, Department of Pharmaceutical Biology and Biotechnology, Wroclaw Medical University, Wrocław, Poland.
Marzenna BartoszewiczDepartment of Pharmaceutical Microbiology and Parasitology, Wroclaw Medical University, Wroclaw, Poland.
Yanfang SunCollege of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
Adam Junka"P.U.M.A." Platform for Unique Model Application, Department of Translative Technologies, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There is an evident need for novel ophthalmic therapeutics that operate outside the conventional antibiotic and chemically synthetized antiseptic paradigms. Medicinal plants represent a chemically rich and cost-effective source of bioactive compounds, though their use requires careful toxicological assessment. Methods: In this study, extracts from four Papaveraceae species - Results: Chemical profiling identified several isoquinoline alkaloids, including berberine, coptisine, protopine, chelidonine, allocryptopine, glaucine, and tetrahydropalmatine. Discussion: Overall, the

Indexed as

antibacterial activityocular infectionspapaveraceae alkaloidstoxicitytranslational phytotherapy

Identifiers

PMID42643345
PMCPMC13503538

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.